Difficulty: Medium
Average Score: 83%
Practice
Under physiological conditions the rate limiting enzyme in the generation of angiotensin II is
Correct answer
A
Rationale
In the context of endocrine pharmacology, understanding the generation of angiotensin II is crucial as it plays a significant role in regulating blood pressure and fluid balance. The rate-limiting step in this process is the conversion of angiotensinogen to angiotensin I by the enzyme renin.
Option A, Renin, is the correct answer because it is the enzyme that initiates the renin-angiotensin-aldosterone system (RAAS) cascade by cleaving angiotensinogen to form angiotensin I. This step is critical in the regulation of blood pressure and fluid balance within the body.
Option B, Angiotensin converting enzyme, is not the rate-limiting enzyme in the generation of angiotensin II. While ACE does convert angiotensin I to angiotensin II, it is not the enzyme responsible for the initial and rate-limiting step in the process.
Option C, Aminopeptidase, is not the correct answer as it is not directly involved in the generation of angiotensin II. Aminopeptidase functions in the degradation of peptides by removing amino acids from the N-terminus, which is a different process than the generation of angiotensin II.
Option D, Angiotensinase, is also not the correct answer as angiotensinase is not a known enzyme involved in the generation of angiotensin II. This option does not play a role in the RAAS pathway.
Understanding the specific enzymes and steps involved in the generation of angiotensin II is important for healthcare professionals, especially when managing conditions such as hypertension. Knowing the rate-limiting enzyme, renin, helps in comprehending the pharmacological targets for medications that aim to modulate the RAAS pathway to control blood pressure. This knowledge is crucial for nursing practice, as it informs patient care decisions and medication management strategies.
Option A, Renin, is the correct answer because it is the enzyme that initiates the renin-angiotensin-aldosterone system (RAAS) cascade by cleaving angiotensinogen to form angiotensin I. This step is critical in the regulation of blood pressure and fluid balance within the body.
Option B, Angiotensin converting enzyme, is not the rate-limiting enzyme in the generation of angiotensin II. While ACE does convert angiotensin I to angiotensin II, it is not the enzyme responsible for the initial and rate-limiting step in the process.
Option C, Aminopeptidase, is not the correct answer as it is not directly involved in the generation of angiotensin II. Aminopeptidase functions in the degradation of peptides by removing amino acids from the N-terminus, which is a different process than the generation of angiotensin II.
Option D, Angiotensinase, is also not the correct answer as angiotensinase is not a known enzyme involved in the generation of angiotensin II. This option does not play a role in the RAAS pathway.
Understanding the specific enzymes and steps involved in the generation of angiotensin II is important for healthcare professionals, especially when managing conditions such as hypertension. Knowing the rate-limiting enzyme, renin, helps in comprehending the pharmacological targets for medications that aim to modulate the RAAS pathway to control blood pressure. This knowledge is crucial for nursing practice, as it informs patient care decisions and medication management strategies.